Skip to main
OM
OM logo

Outset Medical (OM) Stock Forecast & Price Target

Outset Medical (OM) Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Outset Medical Inc has demonstrated a robust demand for its innovative dialysis technology, with management confirming a solid and expanding order pipeline that reflects continued growth from Q4 to Q1. Notably, the company is on track to achieve EBITDA positivity at sales levels of less than $200 million by 2028, bolstered by its ongoing revenue generation from Tablo consoles and consumables. Furthermore, the assurance of sufficient funding to reach profitability enhances the positive outlook for the company's future financial performance.

Bears say

Outset Medical Inc. faces significant challenges due to its reliance on a single product, the Tablo system, which necessitates continuous innovation to remain competitive. The company has not achieved profitability and may not do so for an extended period, raising concerns about its financial sustainability. Additionally, the commercial strategy is heavily dependent on the successful adoption of Tablo in acute care settings, which may not materialize as projected, further straining revenue growth prospects.

Outset Medical (OM) has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outset Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outset Medical (OM) Forecast

Analysts have given Outset Medical (OM) a Hold based on their latest research and market trends.

According to 1 analysts, Outset Medical (OM) has a Hold consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outset Medical (OM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.